Amphastar Pharmaceuticals(AMPH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMPH Amphastar Pharmaceuticals

交易中 02-05 12:58:44 EST

28.85

+0.24

+0.84%

最高29.22	最低28.45	成交量10.80万
今开28.45	昨收28.61	日振幅2.69%
总市值13.26亿	流通市值10.04亿	总股本4,595万
成交额311.56万	换手率0.31%	流通股本3,480万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMPH","market":"US","secType":"STK","nameCN":"Amphastar Pharmaceuticals","latestPrice":28.85,"timestamp":1770314321887,"preClose":28.61,"halted":0,"volume":108010,"delay":0,"changeRate":0.008388675288360783,"floatShares":34803100,"shares":45952174,"eps":2.269251,"marketStatus":"交易中","change":0.24,"latestTime":"02-05 12:58:44 EST","open":28.45,"high":29.2199,"low":28.45,"amount":3115613.6880400004,"amplitude":0.02691,"askPrice":28.87,"askSize":79,"bidPrice":28.81,"bidSize":404,"shortable":3,"etf":0,"ttmEps":2.269251,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770325200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1403668800000,"exchange":"NASDAQ","adjPreClose":28.61,"postHourTrading":{"tag":"盘后","latestPrice":28.61,"preClose":28.61,"latestTime":"16:10 EST","volume":3359,"amount":96086.74,"timestamp":1770239403962,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.557371,"impliedVol":0.4553,"impliedVolPercentile":0.502},"requestUrl":"/m/hq/s/AMPH","defaultTab":"news","newsList":[{"id":"2608159598","title":"Amphastar Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.30%报27.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608159598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608159598?lang=zh_cn&edition=full","pubTime":"2026-02-03 03:08","pubTimestamp":1770059286,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日03时08分，Amphastar Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.30%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.50%。Amphastar Pharmaceuticals, Inc.公司简介：Amphastar Pharmaceuticals Inc 是一家生物制药公司，专注于开发，制造，营销和销售技术上具有挑战性的仿制和专有注射，吸入和鼻内产品，以及胰岛素活性药物成分产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203030806a6cb4253&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203030806a6cb4253&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH","BK4585","BK4007","BK4557","BK4588"],"gpt_icon":0},{"id":"1186841287","title":"Amphastar Pharmaceuticals与南京汉欣医药科技就全合成促肾上腺皮质激素化合物达成授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1186841287","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186841287?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:05","pubTimestamp":1768215918,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals已同南京汉欣医药科技有限公司签署一项授权协议，涉及一款全合成促肾上腺皮质激素化合物的开发与商业化。该合作旨在拓展双方在激素类药物领域的产品管线，为特定内分泌疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4557","BK4585","AMPH","BK4007"],"gpt_icon":0},{"id":"1170023421","title":"安菲斯塔制药：FDA认定公司的特立帕肽与礼来公司的Forteo具有生物等效性和治疗等效性","url":"https://stock-news.laohu8.com/highlight/detail?id=1170023421","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170023421?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:05","pubTimestamp":1765796711,"startTime":"0","endTime":"0","summary":"安菲斯塔制药：FDA认定公司的特立帕肽与礼来公司的Forteo具有生物等效性和治疗等效性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AMPH","BK4588","BK4007","BK4557"],"gpt_icon":0},{"id":"1193841528","title":"安菲斯塔制药公司：巴克莱开始覆盖，并给予平等权重评级；目标价格为30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193841528","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193841528?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:43","pubTimestamp":1765280592,"startTime":"0","endTime":"0","summary":"安菲斯塔制药公司：巴克莱开始覆盖，并给予平等权重评级；目标价格为30美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMPH","BK4585","BK4588","BK4557","BK4007"],"gpt_icon":0},{"id":"1107524050","title":"Amphastar Pharmaceuticals Inc - 协议期限为10年，且可进行续签谈判 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1107524050","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107524050?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:24","pubTimestamp":1761337451,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals Inc - 协议期限为10年，且可进行续签谈判 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4557","AMPH","BK4585"],"gpt_icon":0},{"id":"1144182770","title":"Amphastar Pharmaceuticals任命成都作为Baqsimi在大中华区的独家经销商 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1144182770","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144182770?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:24","pubTimestamp":1761337451,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals任命成都作为Baqsimi在大中华区的独家经销商 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","AMPH","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"1193463099","title":"Amphastar Pharmaceuticals Inc - 10月21日，公司旗下与程工达成分销协议 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1193463099","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193463099?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:24","pubTimestamp":1761337451,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals Inc - 10月21日，公司旗下与程工达成分销协议 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4557","BK4588","AMPH","BK4585"],"gpt_icon":0},{"id":"1185680615","title":"Amphastar Pharmaceuticals与Hanxin签署合同研究协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1185680615","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185680615?lang=zh_cn&edition=full","pubTime":"2025-09-19 04:49","pubTimestamp":1758228559,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals于9月15日与Hanxin签署了一项合同研究协议。该协议的签署标志着两家公司在研发领域的合作关系正式建立。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4557","BK4585","AMPH"],"gpt_icon":0},{"id":"1158003040","title":"异动解读 | 安芙莎制药获Needham上调评级至\"买入\"，股价盘中大涨6.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158003040","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158003040?lang=zh_cn&edition=full","pubTime":"2025-08-12 22:04","pubTimestamp":1755007441,"startTime":"0","endTime":"0","summary":"8月12日周二盘中，安芙莎制药股价大涨6.54%，引起投资者广泛关注。消息面上，知名分析机构Needham对安芙莎制药的投资评级从\"持有\"上调至\"买入\"。虽然Needham尚未披露具体的上调理由，但市场普遍认为，这一评级变化表明安芙莎制药在制药行业的发展潜力得到了专业分析师的认可。这一评级上调无疑增强了投资者对安芙莎制药未来成长性的信心，带动了股价的强劲上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"1155782185","title":"异动解读 | Amphastar Pharmaceuticals获Needham上调评级至\"买入\"，股价盘中大涨6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1155782185","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155782185?lang=zh_cn&edition=full","pubTime":"2025-08-12 22:02","pubTimestamp":1755007367,"startTime":"0","endTime":"0","summary":"8月12日周二，Amphastar Pharmaceuticals股价表现强劲，盘中大涨6.87%，引发市场广泛关注。股价上涨的主要催化剂是知名分析机构Needham对Amphastar Pharmaceuticals的投资评级从\"持有\"上调至\"买入\"。虽然Needham尚未披露具体的上调理由，但业内人士推测，这可能与Amphastar Pharmaceuticals近期的业务表现、产品管线进展或市场竞争地位的改善有关。该评级变化表明Amphastar Pharmaceuticals在制药行业的发展潜力得到了专业分析师的认可，从而带动了投资者的积极情绪，推动股价强劲上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"1111740444","title":"异动解读 | Amphastar Pharmaceuticals盘前大涨5.63%，获Needham上调评级至\"买入\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1111740444","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111740444?lang=zh_cn&edition=full","pubTime":"2025-08-12 21:04","pubTimestamp":1755003866,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals（AMPH）今日盘前股价大涨5.63%，引起投资者广泛关注。\n\n消息面上，知名分析机构Needham对Amphastar Pharmaceuticals的投资评级从\"持有\"上调至\"买入\"。这一积极的评级调整反映了分析师对公司未来发展前景的看好，成为推动股价上涨的主要催化剂。\n\nNeedham的评级上调可能基于Amphastar Pharmaceuticals近期的业务表现、产品管线进展或市场竞争地位的改善。然而，具体的上调理由尚未披露。投资者普遍认为，这一评级变化表明该公司在制药行业的发展潜力得到了专业分析师的认可，从而带动了股价的强劲上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"2558959666","title":"Amphastar Pharmaceuticals, Inc.盘中异动 大幅上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558959666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558959666?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:30","pubTimestamp":1754919026,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时30分，Amphastar Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.00%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.00%。Amphastar Pharmaceuticals, Inc.公司简介：Amphastar Pharmaceuticals Inc 是一家生物制药公司，专注于开发，制造，营销和销售技术上具有挑战性的仿制和专有注射，吸入和鼻内产品，以及胰岛素活性药物成分产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213026a482157e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213026a482157e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH","BK4557","BK4585","BK4007","BK4588"],"gpt_icon":0},{"id":"1116805037","title":"异动解读 | Amphastar制药盘中大涨11.79%，季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1116805037","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116805037?lang=zh_cn&edition=full","pubTime":"2025-08-08 22:01","pubTimestamp":1754661703,"startTime":"0","endTime":"0","summary":"周五盘中，Amphastar制药股价大幅上涨11.79%，引起投资者广泛关注。这一显著涨幅主要源于公司发布的最新季度财报优于市场预期。根据公司公告，截至2025年6月30日的季度调整后每股收益达到0.85美元，显著高于分析师平均预期的0.74美元。值得注意的是，在此次财报公布之前，Amphastar制药的股价今年以来已下跌43.9%。此次积极的财报结果可能标志着公司业务转折点的到来。这一乐观展望可能进一步支撑了投资者的信心，推动股价强劲反弹。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"1136465052","title":"异动解读 | 安芙斯特制药季报超预期，股价盘中大涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136465052","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136465052?lang=zh_cn&edition=full","pubTime":"2025-08-08 22:01","pubTimestamp":1754661698,"startTime":"0","endTime":"0","summary":"安芙斯特制药今日盘中大涨5.41%，引起投资者广泛关注。这一显著涨幅主要源于公司发布的最新季度财报超出市场预期。根据公司公布的财报，截至6月30日的季度调整后每股收益达到85美分，大幅超过分析师平均预期的74美分。值得注意的是，尽管安芙斯特制药今日股价强劲反弹，但公司股价今年累计仍下跌43.9%。分析师对公司保持乐观态度，目前平均评级为\"买入\"，12个月目标价中位数为32.50美元，较上一交易日收盘价21.62美元高出约33.5%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"2557251527","title":"Amphastar Pharmaceuticals, Inc.盘中异动 早盘股价大涨7.26%报23.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557251527","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557251527?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:34","pubTimestamp":1754660061,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日21时34分，Amphastar Pharmaceuticals, Inc.股票出现波动，股价大幅上涨7.26%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为1.02%。其相关个股中，Alpha Teknova, Inc.、Ani Pharmaceuticals, Inc.、Gelteq Limited涨幅较大，Incannex Healthcare Inc.、Shuttle Pharmaceuticals Holdings, Inc.、Akanda Corp.较为活跃，换手率分别为77.75%、2.76%、1.07%，振幅较大的相关个股有Organogenesis Holdings Inc.、Alpha Teknova, Inc.、Eton Pharmaceuticals, Inc.，振幅分别为12.17%、11.06%、10.85%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080821342194d7c97f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080821342194d7c97f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH","BK4585","BK4007","BK4557","BK4588"],"gpt_icon":0},{"id":"1133359932","title":"安福星2025财年Q2业绩会总结及问答精华：Baqsimi推动增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1133359932","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133359932?lang=zh_cn&edition=full","pubTime":"2025-08-08 06:50","pubTimestamp":1754607041,"startTime":"0","endTime":"0","summary":"安福星管理层强调了公司在2025年第二季度的稳健表现，特别是Baqsimi的强劲增长。管理层预计2025年全年销售将保持平稳，并重申Baqsimi的高单位增长和美国市场3%的价格上涨。未来计划包括两个风险调整后的产品发布，以及扩大美国总部的制造能力。调整后净收入为4090万美元，同比下降16%。Baqsimi销售额增长21%，达到4650万美元。Baqsimi的高单位增长和美国市场3%的价格上涨仍在轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMPH"],"gpt_icon":0},{"id":"2517149430","title":"Amphastar Pharmaceuticals, Inc.2024财年实现净利润1.60亿美元，同比增加15.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517149430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517149430?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363258,"startTime":"0","endTime":"0","summary":"3月8日，Amphastar Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为1.60亿美元，同比增加15.94%；其中营业收入为7.32亿美元，同比增加13.66%，每股基本收益为3.29美元。从资产负债表来看，Amphastar Pharmaceuticals, Inc.总负债8.92亿美元，其中短期债务7.04百万美元，资产负债比为1.83，流动比率为3.07。机构评级：截至2025年3月8日，当前有5家机构对Amphastar Pharmaceuticals, Inc.目标价做出预测，其中目标均价为39.80美元，其中最低目标价为36.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000250a2647fca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000250a2647fca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH"],"gpt_icon":0},{"id":"2516657112","title":"Amphastar Pharmaceuticals, Inc.盘中异动 下午盘大幅跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516657112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516657112?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:04","pubTimestamp":1741028653,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时04分，Amphastar Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.06%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为1.04%。Amphastar Pharmaceuticals, Inc.公司简介：Amphastar Pharmaceuticals Inc 是一家生物制药公司，专注于开发、制造、营销和销售技术上具有挑战性的仿制和专有注射、吸入和鼻内产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304030413abe67f78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304030413abe67f78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","BK4585","AMPH","BK4557"],"gpt_icon":0},{"id":"2514320118","title":"Amphastar Pharmaceuticals, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320118","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514320118?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:37","pubTimestamp":1740753470,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时37分，Amphastar Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.02%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.18%。其相关个股中，Organogenesis Holdings Inc.、百利高、Ani Pharmaceuticals, Inc.涨幅较大，Organogenesis Holdings Inc.、大自然药业、Petros Pharmaceuticals, Inc.较为活跃，换手率分别为3.94%、2.57%、2.29%，振幅较大的相关个股有Organogenesis Holdings Inc.、Talphera, Inc.、Evoke Pharma, Inc.，振幅分别为46.58%、8.63%、7.47%。Amphastar Pharmaceuticals, Inc.公司简介：Amphastar Pharmaceuticals Inc 是一家生物制药公司，专注于开发、制造、营销和销售技术上具有挑战性的仿制和专有注射、吸入和鼻内产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822375198967b76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822375198967b76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","BK4585","BK4007","BK4588","AMPH"],"gpt_icon":0},{"id":"1188065952","title":"异动解读 | Amphastar Pharmaceuticals发布2024年第四季度业绩不佳,盘后股价大跌10.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188065952","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188065952?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:06","pubTimestamp":1740693993,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals公司(纳斯达克代码:AMPH)2024年第四季度财报业绩不佳,触发其在盘后交易中大幅下跌10.19%。\n\n根据公司公布的最新财报,Amphastar 2024年第四季度调整后每股收益为0.92美元,低于分析师预期的0.94美元。季度销售额达1.865亿美元,也未能达到预期的1.888亿美元目标。\n\n公司每股收益和营收均未达预期,引发市场对其盈利能力和增长前景的质疑。分析人士指出,该公司可能面临来自仿制药竞争加剧、新药研发进展缓慢、或营运成本过高等挑战。投资者对Amphastar的长期发展潜力失去信心,从而导致股价在盘后交易中大幅下挫。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amphastar.com","stockEarnings":[{"period":"1week","weight":0.0953},{"period":"1month","weight":0.0707},{"period":"3month","weight":0.1808},{"period":"6month","weight":0.2016},{"period":"1year","weight":-0.138},{"period":"ytd","weight":0.0683}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amphastar Pharmaceuticals, Inc.是一家加利福尼亚的公司，成立于1996年2月29日，于2004年7月和amphastar制药公司一家在特拉华成立的公司合并。公司是一家专业制药公司，主要开发，生产，销售市场上通用和专用注射和吸入产品，包括投资组合的市场进入壁垒高，通用和专利产品。大多数公司的产品用于住院或紧急护理的临床设置和主要承包通过集团采购组织和药品批发商。公司的产品主要分布在药企零售。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.032842},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.009483},{"month":3,"riseRate":0.636364,"avgChangeRate":0.039394},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.006986},{"month":5,"riseRate":0.818182,"avgChangeRate":0.067588},{"month":6,"riseRate":0.636364,"avgChangeRate":0.056362},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004743},{"month":8,"riseRate":0.583333,"avgChangeRate":0.055341},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.045989},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.011073},{"month":11,"riseRate":0.75,"avgChangeRate":0.073289},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.000354}],"exchange":"NASDAQ","name":"Amphastar Pharmaceuticals","nameEN":"Amphastar Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amphastar Pharmaceuticals(AMPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Amphastar Pharmaceuticals(AMPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Amphastar Pharmaceuticals,AMPH,Amphastar Pharmaceuticals股票,Amphastar Pharmaceuticals股票老虎,Amphastar Pharmaceuticals股票老虎国际,Amphastar Pharmaceuticals行情,Amphastar Pharmaceuticals股票行情,Amphastar Pharmaceuticals股价,Amphastar Pharmaceuticals股市,Amphastar Pharmaceuticals股票价格,Amphastar Pharmaceuticals股票交易,Amphastar Pharmaceuticals股票购买,Amphastar Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amphastar Pharmaceuticals(AMPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Amphastar Pharmaceuticals(AMPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}